AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 292 min read$GILD

Gilead Sciences Non-GAAP EPS of $2.55 beats by $0.36, revenue of $8.3B beats by $500M (NASDAQ:GILD)

Gilead Sciences (GILD) reported Q3 Non-GAAP EPS of $2.55, beating estimates by $0.36, with revenue of $8.3B, up 6.8% Y/Y and $500M above expectations. Shares rose 1.22% after hours. For 2026, Gilead raised product sales guidance to $31B-$31.3B, excluding Veklury, and adjusted EPS loss guidance to $(1.20)-$(0.85).

Original reporting
seekingalpha.com
Published Oct 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GILD
Bullish
high confidence
Mentioned
$GILD
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$GILDBullishHigh
01

Why it matters

The earnings beat on EPS is offset by a non‑GAAP loss wider than consensus, likely leading to a modest sell‑off.

02

Market read

First‑report earnings release for a large‑cap biotech; provides fresh data for traders.

03

What to watch

Potential upcoming product launches and Veklury sales stability are not reflected in the guidance.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Gilead Sciences released its Q3 2026 earnings and updated full‑year guidance.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Gilead Sciences reported Q3 Non-GAAP EPS of $2.55 beating expectations and provided full-year product sales guidance.

Expected impact

likely downside pressure as market prices in weaker non‑GAAP loss guidance

Evidence & confidence

EPS beat is modest, while non‑GAAP loss per share of -$0.85 exceeds consensus of -$0.45 and guidance is only modestly above prior ranges.

Market effects

Sector

Biopharma earnings may influence peer valuations and sector sentiment.

Regional

U.S. market participants will adjust exposure to antiviral and hepatitis C products.

Global

Gilead's guidance affects global investors tracking hepatitis C and HIV treatment markets.

Counterpoint

What could challenge this read

Despite the non‑GAAP loss miss, the modest revenue growth could support a short‑term bounce.

Key entities

  • company
    Gilead Sciences

    U.S. biopharma company reporting earnings.

Read at source← All news

StoryGilead beats Q3 2026 earnings, lifts full‑year sales outlook on strong HIV growth

Also covered by

5 outlets

Related articles

OCT 30
$GILDMedAI 8/10

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead Sciences (GILD) raised its 2026 sales outlook to $31B-$31.3B, citing strong Q3 growth. HIV revenues are expected to grow 12% in 2026, but Biktarvy faces a $1.5B revenue headwind in 2028 due to Medicare pricing. Q3 earnings beat estimates at $2.55 per share, with revenues of $8.3B. The company also detailed advancements in oncology and inflammation pipelines.

zacks.com3 min
OCT 30
$GILDHighAI 9/10

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead Sciences reported Q3 2026 adjusted earnings of $2.55 per share, beating estimates. Revenues rose 6.8% to $8.3B, driven by HIV drugs and Trodelvy. HIV sales grew 18% to $6.25B, while Trodelvy sales jumped 42% to $506M. GILD raised its 2026 product sales guidance to $31-$31.3B. Cell Therapy revenues declined 18% to $355M. Shares have gained 38.2% year to date.

zacks.com6 min